SPECTAcolor viable next generation multinational cancer clinical trial infrastructure

SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. Successfully implemented across 19 clinical centers located in nine countries in Europe, it has now recruited over 500 patients since launch in September 2013. Pathological review and core analyses of tumor blocks shipped to the central biobank deemed over 98 percent of the samples were adequate. This demonstrates the feasibility of this logistically complex infrastructure for conducting multinational next generation trials. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *